Just a few years back, many food companies thought that the rise of GLP-1 weight-loss medications would be a short trend. Now, they see it’s a major shift in how we think about food and nutrition. Gali Artzi, the chief technology officer at PeakBridge, says we’re moving away from the traditional “calorie economy” towards a new focus on “performance nutrition.”
The market for foods that complement GLP-1 treatments is huge, currently valued at about $62.2 billion. It’s expected to grow to $157.5 billion by 2035. A big piece of this growth will come from products aimed at filling nutritional gaps for GLP-1 users. These medications can reduce calorie intake by about 21% each year, leading to deficiencies in vital nutrients like iron and vitamin D.
Artzi emphasizes that as people using GLP-1 drugs like Ozempic begin to favor fresh foods over traditional snacks and desserts, the market must adapt. “Every bite has to work harder for us,” she notes, reflecting a shift to more purposeful eating habits.
Maha Tahiri, CEO of S2B, believes the industry is facing a new type of consumer. Companies built on impulsive buying are being challenged to rethink their strategies. The key is understanding that the needs of GLP-1 users evolve, especially as they move in and out of treatments. For instance, side effects from these medications, like nausea and diarrhea, can lead to people stopping their use after a year, making weight regain common.
This offers food brands a chance to support users at every step of their journey with services like lifestyle coaching and telehealth. Companies can also rebrand existing products to connect better with consumers, improving awareness about nutritional benefits.
Innovation doesn’t stop at rebranding. As Tahiri points out, different age groups have different dietary needs. For example, food for a toddler isn’t the same as for a baby. Food companies are exploring new product formats, such as “microportions,” to cater to shifting needs.
Interestingly, many consumers are now turning to AI like ChatGPT for dietary advice. This trend highlights the importance of understanding what GLP-1 users are seeking. Companies that invest in research and development stand to gain from creating tailored products that meet these new demands.
Artzi also mentions that it’s crucial to normalize the discussion around GLP-1s. As seen in a recent Super Bowl ad featuring celebrities, these medications are being framed less as strict prescriptions and more as lifestyle choices.
To sum up, the landscape of nutrition is changing dramatically as GLP-1 medications become more common. Understanding and adapting to the needs of these users will be key for food companies looking to thrive in this new market.
Source link
